Merck to Showcase New Cardiovascular Disease Management and Patient Care Data at European Society of Cardiology Congress 2025
ByAinvest
Monday, Aug 25, 2025 6:47 am ET1min read
MRK--
Merck announces new data on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF) at the European Society of Cardiology Congress 2025. The data includes clinical trial and outcomes research focusing on treatment patterns and burdens for patients with ASCVD, as well as research on WINREVAIR and VERQUVO in PH and HFrEF. The company will also host three symposia throughout the congress.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet